Johnson & Johnson announced preliminary results from a Phase 1b study of pasritamig (JNJ-78278343), a bispecific T-cell engaging antibody targeting CD3 and KLK2, in combination with docetaxel for metastatic castration-resistant prostate cancer. As of Dec. 9, 2025, 51 patients had received the combination; PSA reductions of at least 50% were reported in 64.7% of patients overall and 75.0% of taxane-naïve patients, with no cytokine release syndrome or treatment-related deaths reported. The results were presented for the first time at the 2026 ASCO Genitourinary Cancers Symposium (Abstract #171).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202602261430PR_NEWS_USPR_____NY93488) on February 26, 2026, and is solely responsible for the information contained therein.